Article directory

TB 500 regulatory update

TB 500 FDA Advisory Vote: What the 8 to 6 Result Means

TB 500 received a favorable recommendation from FDA advisers during the July 2026 meeting. The vote concerned a compounding list, not approval of a drug or retail product.

Updated July 29, 2026Educational regulatory coverage8 minute read
Key point
TB 500 was recommended, not approved.

The 8 to 6 vote, with one abstention, was a nonbinding recommendation about possible Section 503A compounding eligibility.

The vote

TB 500 received a favorable recommendation.

On July 23, 2026, participating advisers voted 8 to 6, with one abstention, to recommend TB 500 related bulk drug substances for potential inclusion on the Section 503A Bulks List.

8Votes in favor
6Votes opposed
1Abstention

FDA's meeting record identifies TB 500 free base and TB 500 acetate, and notes that the agency reviewed wound healing as the nominated use. FDA staff had proposed that the substances not be included.

Regulatory meaning

A recommendation is one step, not the finish line.

The committee advised FDA to consider TB 500 for the 503A compounding pathway. The agency is not bound by that result. Formal status depends on later FDA action.

The limits

What the TB 500 vote did not do

  • It did not approve TB 500 as a drug.
  • It did not establish safety or effectiveness for wound healing, recovery, tissue repair, or another use.
  • It did not approve Neuvéra's BPC 157 plus TB 500 strip.
  • It did not immediately authorize routine pharmacy compounding.
FDA's standing concern: FDA says it has not identified human exposure data for drug products containing the thymosin beta 4 fragment known as TB 500 and flags potential impurity and immunogenicity risks.

What to watch

Future FDA action will determine formal status.

The most reliable next signal will come from FDA's official compounding materials. Until then, accurate language is “recommended by an FDA advisory committee for the 503A list,” not “FDA approved” or “legalized.”

Format education

The committee did not review retail strip products.

The committee's question involved bulk drug substances for potential pharmacy compounding. It did not review Neuvéra packaging, delivery format, dosing, claims, or product quality.

Adult using a Neuvéra daily strip
Neuvéra Recovery and Repair daily strip routine

Related Neuvéra routine

Recovery and Repair

A pre-measured strip format created for a straightforward daily routine. No mixing or measuring.

$129

First order: save 10%

View Recovery and Repair

Commercial disclosure: Strips Over Needles may direct readers to products sold by Neuvéra. The committee vote discussed above did not evaluate or endorse this product.

Primary and independent reporting

Sources

  1. FDA: July 23 and 24, 2026 Pharmacy Compounding Advisory Committee meeting record
  2. FDA: Bulk drug substances that may present significant safety risks
  3. Reuters: FDA advisers back BPC 157, KPV, TB 500 and MOTS c
  4. TIME: Overview of the committee decisions and debate
  5. ABC News: Six peptides recommended by FDA advisers

Published July 29, 2026. This article is educational and does not provide medical advice. Consult a qualified professional about personal health decisions.

Continue reading

Related regulatory guides

Full roundupSee all seven committee resultsBPC 157What the related 8 to 6 recommendation meansSemaxWhat the 8 to 5 recommendation means